Clinical trial
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed…
NCT00049179 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00049179 |
|---|---|
| Title | S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia |
| Official title | A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, gemtuzumab ozogamicin |
| Enrollment | 33 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Oct 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: